William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on July 31.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sami Corwin has given his Buy rating due to a combination of factors, primarily focusing on Tenaya Therapeutics’ promising clinical developments and financial stability. The company is set to release significant clinical data for its TN-201 and TN-401 programs in the fourth quarter of 2025, which could potentially demonstrate the efficacy of their treatments for cardiac conditions. This anticipated data release is a crucial milestone that could enhance the company’s value and investor confidence.
Furthermore, despite reporting a loss in the second quarter of 2025, Tenaya maintains a solid financial position with $71.7 million in cash and equivalents, which is projected to support operations into the second half of 2026. This financial runway, combined with the strategic focus on advancing their clinical programs, underpins the Buy rating as the company is well-positioned to capitalize on upcoming clinical successes and manage its operational expenses effectively.
In another report released on July 31, LifeSci Capital also maintained a Buy rating on the stock with a $3.00 price target.